ALK-Abello A/S/€ALKB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ALK-Abello A/S
ALK-Abelló A/S is a Danish company specializing in the development and production of allergy immunotherapy products. The company operates within the pharmaceutical industry, providing allergy treatments that include tablets, injections, and drops. Notably, ALK-Abelló focuses on allergy immunotherapy for respiratory allergies, such as allergies to grass, tree pollen, house dust mites, and animal dander. Headquartered in Hørsholm, Denmark, ALK-Abelló serves a global market with a significant presence in Europe and North America. The company's strategic focus on research and development in allergy solutions and its specialized product portfolio underscore its commitment to addressing a critical niche in the healthcare sector.
- Ticker
- €ALKB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 2,773
- Headquarters
- Horsholm, Denmark
- Website
- www.alk.net
ALK-Abello A/S Metrics
BasicAdvanced
€7.2B
39.67
€0.82
0.71
€0.21
0.66%
Price and volume
Market cap
€7.2B
Beta
0.71
52-week high
€36.48
52-week low
€26.02
Average daily volume
224K
Dividend rate
€0.21
Financial strength
Current ratio
3.457
Quick ratio
2.087
Long term debt to equity
0.052
Total debt to equity
0.061
Dividend payout ratio (TTM)
26.18%
Interest coverage (TTM)
183.50%
Profitability
EBITDA (TTM)
280.311
Gross margin (TTM)
68.18%
Net profit margin (TTM)
19.86%
Operating margin (TTM)
26.87%
Effective tax rate (TTM)
26.58%
Revenue per employee (TTM)
€329,140
Management effectiveness
Return on assets (TTM)
12.75%
Return on equity (TTM)
21.21%
Valuation
Price to earnings (TTM)
39.672
Price to revenue (TTM)
7.872
Price to book
7.76
Price to tangible book (TTM)
10.43
Price to free cash flow (TTM)
29.849
Free cash flow yield (TTM)
3.35%
Free cash flow per share (TTM)
1.084
Dividend yield (TTM)
0.66%
Forward dividend yield
0.66%
Growth
Revenue change (TTM)
16.52%
Earnings per share change (TTM)
36.38%
3-year revenue growth (CAGR)
13.42%
10-year revenue growth (CAGR)
8.66%
3-year earnings per share growth (CAGR)
55.75%
10-year earnings per share growth (CAGR)
11.69%
10-year dividend per share growth (CAGR)
20.40%
What the Analysts think about ALK-Abello A/S
Analyst ratings (Buy, Hold, Sell) for ALK-Abello A/S stock.
Analyst projections of the future price of ALK-Abello A/S stock.
Bulls say / Bears say
ALK raised its 2026 revenue growth forecast to 16–17% and its EBIT margin outlook to about 27%, citing strong tablet sales across regions. This signals broad-based momentum and improving operating leverage. (ALK)
A Chinese phase 3 trial of ALK’s house-dust-mite tablet met its primary objective and showed a familiar safety profile. A regulatory filing is planned for the first half of 2027, opening a potential growth path in a large, underpenetrated market if approved. (ALK)
UK health authorities recommended ALK’s house-dust-mite and tree-pollen tablets for eligible children whose allergic rhinitis is not controlled by symptom-relief medicines. Public-system access could broaden the customer base for its existing products. (The Pharmaletter)
Germany’s mandatory rebate on prescription medicines is set to rise from 7% to 15.5% in 2027. That could pressure margins in an important market unless ALK offsets the increase. (Roic AI)
ALK flagged tough comparisons with the strong second half of 2025 and possible swings in shipments to China and Japan. These factors could make near-term growth more uneven than its first-half performance suggests. (Investing.com)
The expanded Catalent supply agreement commits ALK to about DKK 500 million over three years, while the added tablet capacity is not expected until the early 2030s. The cash commitment may weigh on near-term cash generation well before the new capacity contributes. (ALK)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
ALK-Abello A/S Financial Performance
Revenues and expenses
ALK-Abello A/S Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ALK-Abello A/S
AllEURUSDGBP
Fund name | Fund size | €ALKB weighting |
|---|---|---|
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.04% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.04% |
Vanguard ESG Global All Cap$V3AA | $1.1B | 0.01% |
Vanguard ESG Global All Cap£V3AM | $678M | 0.01% |
Vanguard ESG Global All Cap£V3AB | $1.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.